[go: up one dir, main page]

AU1362101A - Novel traf family proteins - Google Patents

Novel traf family proteins

Info

Publication number
AU1362101A
AU1362101A AU13621/01A AU1362101A AU1362101A AU 1362101 A AU1362101 A AU 1362101A AU 13621/01 A AU13621/01 A AU 13621/01A AU 1362101 A AU1362101 A AU 1362101A AU 1362101 A AU1362101 A AU 1362101A
Authority
AU
Australia
Prior art keywords
family proteins
traf family
novel traf
novel
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13621/01A
Inventor
John C Reed
Juan M. Zapata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of AU1362101A publication Critical patent/AU1362101A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU13621/01A 1999-11-05 2000-11-03 Novel traf family proteins Abandoned AU1362101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43478499A 1999-11-05 1999-11-05
US09434784 1999-11-05
PCT/US2000/030533 WO2001032696A2 (en) 1999-11-05 2000-11-03 Traf family proteins

Publications (1)

Publication Number Publication Date
AU1362101A true AU1362101A (en) 2001-05-14

Family

ID=23725690

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13621/01A Abandoned AU1362101A (en) 1999-11-05 2000-11-03 Novel traf family proteins

Country Status (4)

Country Link
EP (1) EP1228088A2 (en)
JP (1) JP2003512857A (en)
AU (1) AU1362101A (en)
WO (1) WO2001032696A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425538B2 (en) 2002-03-30 2008-09-16 The Trustess Of Columbia University In The City Of New York HAUSP-p53 interaction and uses thereof
US7498134B2 (en) 2002-03-30 2009-03-03 The Trustees Of Columbia University In The City Of New York HAUSP-Mdm2 interaction and uses thereof
WO2004011636A2 (en) * 2002-07-31 2004-02-05 The Babraham Institute Method of enzymatic deubiquitination
WO2008086502A2 (en) * 2007-01-10 2008-07-17 University Of Chicago Molecular marker for clear renal cell carcinoma
TWI502199B (en) * 2013-05-23 2015-10-01 Univ Nat Central Use of tumor necrosis factor (tnf) receptor-associated factor 7 (traf7) as biomarkers for systemic lupus erythematosus (sle), method and kit for detecting of human with sle
JP6320752B2 (en) * 2013-12-28 2018-05-09 国立大学法人愛媛大学 Novel ubiquitin ligase and method for using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020723A1 (en) * 1994-12-30 1996-07-11 Brigham & Women's Hospital Controlling traf-mediated signals

Also Published As

Publication number Publication date
WO2001032696A3 (en) 2002-01-17
WO2001032696A2 (en) 2001-05-10
EP1228088A2 (en) 2002-08-07
JP2003512857A (en) 2003-04-08

Similar Documents

Publication Publication Date Title
AU1290001A (en) Antibodies
AU4935000A (en) Antibodies
AU1890300A (en) Novel interferon-alpha
AU6045900A (en) Interaction-activated proteins
AU2880400A (en) Tnf-related proteins
GB9921125D0 (en) Proteins
AU5706000A (en) Useful polypeptide
AU1362101A (en) Novel traf family proteins
AU2452301A (en) Protein methylarginine-specific antibodies
AU4081000A (en) Uncoupling proteins
AU2691500A (en) Novel polypeptide
AU1881200A (en) Novel proteins
AU2359301A (en) Novel ss-defensins
AU4778600A (en) Novel polypeptide
AU6983000A (en) Chimeric proteins
AU2061201A (en) Mammalian dishevelled-associated proteins
AU1540701A (en) Novel protein
AU2002500A (en) Novel protein
AU7304600A (en) Novel protein
AU3506800A (en) Leukocyte- and blood-associated proteins
AU2109200A (en) Polypeptide
AU1228201A (en) Umlr polypeptides
AU6444600A (en) New protein
AU5449200A (en) Cytoskeleton-associated proteins
AU2985200A (en) Novel sialoadhesins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase